• By ICR Secretariat
• Posted Tuesday, September 19, 2023

Site Enablement: How Sponsors and CROs Can Enhance Their Clinical Trials in a Competitive Landscape

https://www.fiercepharma.com/sponsored/site-enablement-how-sponsors-and-cros-can-enhance-their-clinical-trials-competitive

The evolution of clinical research has been dependent on the conversion of Healthcare Organizations (HCOs) to clinical research sites, along with the conversion of Healthcare Providers (HCPs) to Principal Investigators (PIs). These conversions are critical to advancing medicine and providing cutting-edge treatment to patients, but in the current clinical research landscape increasingly complex clinical trial protocols, demanding data collection requirements, and constricted study timelines have been stalling HCO and HCP conversion rates. The pace of clinical trials being initiated now exceeds the amount of clinical research sites available to conduct these trials.